LGALS3 and colitis: Inhibition of Gal-3 in MSCs did not alter their potential to prevent the development of DSS-induced colitis, according to survival rate (Figure 1(b)) (P < 0.05; Fisher's exact test), clinical parameters (Figure 1(c)), and colon length (Figure 1(d)) (P < 0.05; Student's t-test).